Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography

This study has been completed.
Sponsor:
Information provided by:
Korea University Guro Hospital
ClinicalTrials.gov Identifier:
NCT01139827
First received: June 8, 2010
Last updated: NA
Last verified: February 2010
History: No changes posted

June 8, 2010
June 8, 2010
September 2009
February 2010   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Association Between Framingham Risk Score, hsCRP and Vascular Inflammation: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
Not Provided

Framingham risk score is well known screening tool that detect cardiovascular (CV) risk. But it is not suitable for CV risk in mild risk group. So 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a new imaging technique for detecting vascular inflammation within atherosclerotic plaques and hsCRP is also arising detection tool of CV risk.

The investigators are examining this association in normal and impaired glucose tolerance patients groups.

We examined vascular inflammation using FDG-PET scan in 178 subjects (Normal and impaired glucose tolerance groups). Vascular 18F-FDG uptake was measured as both the mean and maximum blood-normalized standardized uptake value (SUV), known as the target-to-background ratio (TBR). And We analyzed that the association with Framingham risk score, hs CRP and vascular inflammation by FDG-PET scan.

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

The subjects underwent routine health checkups at Korea University Guro Hospital. Patients with DM or gestational diabetes were not included.

Cardiovascular Risk
Not Provided
  • normal
    normal group has no diabetes.
  • IGT
    IGT group has impaired fasting glucose or impaired glucose tolerance.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
178
February 2010
February 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • healthy subjects

Exclusion Criteria:

  • a history of cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization)
  • active inflammatory disease, recent active infection
  • stage 2 hypertension (resting blood pressure, ≥ 160/100 mmHg)
  • diabetes mellitus
  • systemic disorders such as severe hepatic, renal, and hematologic diseases
  • taking drugs known to interfere with vascular inflammation measured by FDG-PET.
Both
16 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01139827
PET(FRS-CRP)
Yes
Not Provided
Korea University Guro Hospital
Not Provided
Not Provided
Korea University Guro Hospital
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP